Gene therapy and hospital pharmacy: the experience of the Hospital Pharmacy unit of L. Vanvitelli university hospital

AboutOpen

View Publication Info
 
 
Field Value
 
Title Gene therapy and hospital pharmacy: the experience of the Hospital Pharmacy unit of L. Vanvitelli university hospital
 
Creator Dubuis, Giovanni
Marrone, Francesca
Russo, Francesco
Ziccardi, Stefania
Annibale, Rosa
 
Subject voretigene neparvovec
Terapia Genica
Farmacia ospedaliera
 
Description Background: Since hospital use of gene therapy requires close cooperation between doctors and pharmacists to ensure correct drug handling and administration, it is essential to define standard operating procedures (SOPs) for each phase of the process to ensure therapeutic success in compliance with the safety of patient and healthcare professionals. Among the available gene therapy medicines, voretigene neparvovec is used to treat hereditary dystrophy of the retina caused by biallelic mutations in the RPE65 gene. The aim of this article is to describe the experience of the Hospital Pharmacy unit of L. Vanvitelli university hospital in the management of treatment with voretigene neparvovec in the first two pediatric patients treated in Italy.
Methods: SOPs were developed for all phases of gene therapy management process (procurement, receipt, storage, handling, transport of the finished product and waste disposal). Particular attention was paid to the training of personnel involved, to ensure maximum compliance with the procedures at all stages of the process.
Results: SOPs were developed according to the European Association of Hospital Pharmacist (EAHP) policies and in full agreement with the operating procedures established by the manufacturer, ensuring correct storage and handling of the drug, as well as safe administration to patients.
Conclusions: This example confirms the importance of close collaboration in a multidisciplinary team between hospital pharmacists, ophthalmologists experienced in the treatment of patients with hereditary retinal dystrophies and surgeons experienced in subretinal surgery to ensure the correct management of gene therapy with voretigene neparvovec, through compliance with shared operating procedures.
 
Publisher AboutScience srl - Piazza Duca d'Aosta 12 - 20124 Milano MI (Italy)
 
Date 2021-08-05
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Original Research Article
 
Format application/pdf
application/epub+zip
text/html
 
Identifier https://journals.aboutscience.eu/index.php/aboutopen/article/view/2260
10.33393/ao.2021.2260
 
Source AboutOpen; Vol. 8 No. 1 (2021): January-December 2021; 74-80
AboutOpen; V. 8 N. 1 (2021): January-December 2021; 74-80
2465-2628
 
Language eng
 
Relation https://journals.aboutscience.eu/index.php/aboutopen/article/view/2260/2416
https://journals.aboutscience.eu/index.php/aboutopen/article/view/2260/2417
https://journals.aboutscience.eu/index.php/aboutopen/article/view/2260/2418
 
Rights Copyright (c) 2021 Giovanni Dubuis, Francesca Marrone, Francesco Russo, Stefania Ziccardi, Rosa Annibale
https://creativecommons.org/licenses/by-nc/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library